The board of directors of Jacobio Pharmaceuticals Group Co., Ltd. announced that, the Company will present its clinical results in the oral abstract session at 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. The Company continues to explore the application of Glecirasib in pancreatic cancer and other solid tumor harboring KRAS G12C mutation. The registrational pivotal clinical study for pancreatic cancer of Glecirasib was approved by Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China in July 2023, which became the first global pancreatic cancer KRAS G12C registrational clinical study.

The study results will be used to submit New Drug Application (NDA) for pancreatic cancer. In August 2023, based on the clinical efficacy and safety data from ongoing Phase I/II clinical trials, Glecirasib was granted breakthrough therapy designation (BTD) by the CDE for the pancreatic cancer patients with a KRAS G12C mutation who have progressed after frontline standard care treatment. Pancreatic cancer is a malignant tumor and there is a lack of effective treatment currently.

The five-year overall survival rate is only 5%. The BTD will expedite the clinical development of Glecirasib and accelerate its early access to the patients.